Moxifloxacin hydrochloride (Mylan) is available as a single-use (preservative-free), premixed, ready-to-use solution of moxifloxacin 400 mg in 250 mL of sodium chloride 0.8% in a flexible container.3175 Hydrochloric acid and/or sodium hydroxide may have been added to adjust the pH.3175 No further dilution of the solution is necessary.3175
Moxifloxacin hydrochloride (Fresenius Kabi) also is available as a single-use, premixed, ready-to-use solution of moxifloxacin 400 mg in a flexible plastic (Freeflex) container.3176 Each 250-mL bag also contains sodium acetate trihydrate 1702.5 mg and disodium sulfate 2840 mg in water for injection.3176 Sulfuric acid may have been added to adjust the pH.3176
Equivalency
Moxifloxacin hydrochloride 437.5 mg is equivalent to moxifloxacin 400 mg.3176
pH
The pH of moxifloxacin hydrochloride (Mylan) solution is from 4.1 to 4.6.3175 The pH of moxifloxacin hydrochloride (Fresenius Kabi) solution is from 5 to 6.3176
Sodium Content
Each 250 mL of moxifloxacin hydrochloride (Mylan) solution contains approximately 34.2 mEq (787 mg) of sodium.3175
Each 250 mL of moxifloxacin hydrochloride (Fresenius Kabi) solution contains approximately 52.5 mEq (1207 mg) of sodium.3176
Trade Name(s)
Avelox
Moxifloxacin hydrochloride is administered intravenously by slow infusion over 60 minutes.3175; 3176 The solution may be infused directly or through a Y-type infusion set.3175; 3176 The solution must not be infused rapidly or as a bolus; it also is not intended for intra-arterial, intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.3175; 3176
Moxifloxacin hydrochloride should not be infused simultaneously through a line being used to administer other drugs.3175; 3176 If a common intravenous line is being used to administer other drugs in addition to moxifloxacin hydrochloride, the infusion line should be flushed prior to and following infusion of moxifloxacin hydrochloride solution with a compatible infusion solution.3175; 3176
Moxifloxacin hydrochloride injection is a clear yellow solution.3175; 3176 One manufacturer notes that this yellow color is not affected by nor indicative of the stability of the product.3175
Intact containers of moxifloxacin hydrochloride should be stored at controlled room temperature.3175; 3176 The solution should not be refrigerated because precipitation may result.3175; 3176 Moxifloxacin hydrochloride (Fresenius Kabi) solution should be stored in its overwrap to protect from light until immediately prior to use.3176
Moxifloxacin hydrochloride solution should be visually inspected for particulate matter and discoloration prior to administration; if particulate matter is present or discoloration occurs, the solution should not be used.3175; 3176 Any unused portion of the solution should be discarded.3175; 3176
Plasticizer Leaching
Moxifloxacin hydrochloride solution (Fresenius Kabi) is in contact with polypropylene contained in the flexible plastic (Freeflex) container and can leach out certain chemical components of the plastic in very small amounts within the expiration period.3176 The leachable compounds were all within acceptable limits based on animal toxicology studies.3176
Y-Site Injection Compatibility (1:1 Mixture)
Additional Compatibility Information
Peritoneal Dialysis Solutions
Moxifloxacin hydrochloride 25 mg/mL in 2 peritoneal dialysis solutions was evaluated for stability. No color change or precipitation occurred. In Dianeal PD1 1.36% and 3.86%, moxifloxacin hydrochloride lost 2% and 9%, respectively, in 14 days at 4°C, and 3% and 11%, respectively, in 7 days at 25°C. Losses at 37°C were higher. In Dianeal PD1 1.36%, 10% loss occurred in 3 days; in Dianeal PD1 3.86%, 7% loss occurred in 12 hours and 13% loss occurred in 24 hours.2712
For a list of references cited in the text of this monograph, search the monograph titled References.